Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

1.9K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
1.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simvastatin Treatment in Patients with Liver Cirrhosis: a Phase II Randomized Placebo Controlled Trial Shows Reduction in IL-6 Levels.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain.

Communications biology·2026
Same author

Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML.

Oncogenesis·2026
Same author

Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Cancer immunology research·2026
Same author

Development of a SIN1 Targeting Inhibitor as a Novel Therapeutic Approach for the Treatment of Malignancies.

Molecular cancer therapeutics·2025
Same author

Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade.

Molecular cancer therapeutics·2025

Related Experiment Video

Updated: Aug 16, 2025

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

13.7K

Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.

Sarah E Fenton1,2, Markella Zannikou1,2, Liliana Ilut1

  • 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

Molecular Cancer Research : MCR
|December 27, 2022
PubMed
Summary

Targeting Unc-51 like kinase 1 (ULK1) may overcome resistance to immune checkpoint inhibitors (ICI) in melanoma. Inhibiting ULK1 reduces immunosuppressive genes and enhances ICI therapy effectiveness, improving patient outcomes.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K

Related Experiment Videos

Last Updated: Aug 16, 2025

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

13.7K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, but resistance remains a significant challenge.
  • Interferon-gamma (IFNγ) signaling plays a dual role, promoting response or resistance to ICIs depending on context.
  • Chronic IFNγ signaling can induce immunosuppressive genes, contributing to therapeutic resistance.

Purpose of the Study:

  • To investigate the role of Unc-51 like kinase 1 (ULK1) in IFNγ-mediated immunosuppression in melanoma.
  • To determine if ULK1 is a druggable target to overcome resistance to ICIs in melanoma.

Main Methods:

  • Correlating ULK1 levels with patient survival in melanoma.
  • Overexpressing or inhibiting ULK1 in melanoma cells to assess effects on IFNγ-stimulated genes.
  • Investigating ULK1's interaction with IRF1 and its role in regulating the PD-L1 promoter.
  • Evaluating the efficacy of ULK1 inhibition combined with anti-PD-1 therapy in vivo.

Main Results:

  • High ULK1 levels correlate with poor melanoma patient survival.
  • ULK1 overexpression enhances IFNγ-induced immunosuppressive genes while minimally affecting immunostimulatory genes.
  • ULK1 inhibition reduces IFNγ-induced immunosuppressive gene expression.
  • ULK1 interacts with IRF1, influencing its binding to the PD-L1 promoter.
  • Combined ULK1 inhibition and anti-PD-1 therapy reduced tumor growth in vivo.

Conclusions:

  • ULK1 is activated downstream of IFNγ signaling and promotes melanoma immunosuppression.
  • Targeting ULK1 represents a novel strategy to overcome resistance to ICIs in melanoma.
  • Combining ULK1 inhibition with ICIs may improve treatment response and outcomes for melanoma patients.